2020
DOI: 10.1002/alz.12164
|View full text |Cite
|
Sign up to set email alerts
|

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Abstract: Introduction: The APECS and AMARANTH trials showed that beta-secretase (BACE) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early Alzheimer's disease. Here, the performance on secondary and exploratory cognitive measures in both studies is reported. Methods: APECS (verubecestat) and AMARANTH (lanabecestat) were randomized, double-blind, placebo-controlled, parallel-group, 104-week clinical trials conducted by different sponsors. Measur… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2

Citation Types

0
37
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 66 publications
(37 citation statements)
references
References 22 publications
0
37
0
Order By: Relevance
“…Therefore, BACE1 has been considered a prime therapeutic drug target for lowering Aβ levels in the AD brain. However, clinical trials based on BACE inhibitors verubecestat and atabecestat were discontinued due to a modest worsening of cognitive function and other adverse effects including the onset of psychiatric symptoms (9)(10)(11)(12)(13). More recently, Biogen and Eisai discontinued two phase-III trials (with BACE inhibitor elenbecestat) due to an unfavorable risk-benefit ratio.…”
mentioning
confidence: 99%
“…Therefore, BACE1 has been considered a prime therapeutic drug target for lowering Aβ levels in the AD brain. However, clinical trials based on BACE inhibitors verubecestat and atabecestat were discontinued due to a modest worsening of cognitive function and other adverse effects including the onset of psychiatric symptoms (9)(10)(11)(12)(13). More recently, Biogen and Eisai discontinued two phase-III trials (with BACE inhibitor elenbecestat) due to an unfavorable risk-benefit ratio.…”
mentioning
confidence: 99%
“…This was impressively shown for β-amyloid PET which revealed post hoc that β-amyloidmodifying trials were initiated with more than one-third of β-amyloid-negative patients that could likely not profit from the therapy [26]. Consequently a positive β-amyloid PET was implemented as a screening criterion in many phase III trials, including the β-amyloid antibody aducanumab [27] and the beta-secretase inhibitors verubecestat and lanabecestat [28].…”
Section: Discussionmentioning
confidence: 99%
“…This was impressively shown for β-amyloid PET which revealed post hoc that β-amyloid-modifying trials were initiated with more than one third of β-amyloid-negative patients that could likely not pro t from the therapy [25]. Consequently a positive β-amyloid PET was implemented as a screening criterion in many phase III trials, including the β-amyloid antibody aducanumab [26] and the beta-secretase inhibitors verubecestat and lanabecestat [27]. [ 18 F]PI-2620 yielded a high sensitivity for detection of patients with PSP in our recent multi-center evaluation and could potentially serve as a screening criterion in anti-tau PSP trials [5].…”
Section: Discussionmentioning
confidence: 99%